viewBioasis Technologies Inc.

Bioasis Technologies and Chiesi Group announce strategic alliance to treat lysosomal storage disorders

Under the terms of the agreement, Bioasis will get an upfront payment of US$3 million

Bioasis Technologies Inc. - Bioasis and Chiesi Group announce strategic alliance to treat lysosomal storage disorders
Chiesi Group, parent of Chiesi Global Rare Diseases, will be responsible for research, development and commercialization costs of the LSD programs

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) and Chiesi Global Rare Diseases have entered into a licensing agreement for Bioasis’ xB3 BBB platform technology to treat rare diseases with a focus on four undisclosed lysosomal storage disorders (LSDs).

The company's stock traded up Tuesday by 26% to $0.23 a share in New York and rose 17% to C$.031 a share in Toronto.  

Under the terms of the agreement, international research-focused healthcare firm Chiesi Group, the parent of Chiesi Global Rare Diseases, will pay Bioasis an upfront payment of US$3 million. 

Bioasis, based in Guilford, Connecticut, may also be eligible to receive additional development, regulatory and commercial milestone payments of up to US$138 million, as well as additional royalties on net sales of licensed products. 

WATCH: Bioasis Technologies says revenue potential for brain metastasis of breast cancer is $404M 

Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.

LSDs are inherited disorders resulting from a lack of specific enzymes that break down certain lipids (fats) or carbohydrates (sugars) in the body cells.

“With this collaboration, we are taking our commitment to bringing innovative therapies to rare disease patients, including those living with LSDs, to an entirely new level,” said Giacomo Chiesi, head of Chiesi Global Rare Diseases, in a statement Monday.

“The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood-brain barrier. We look forward to working closely with the Bioasis team in advancing several new LSD clinical development programs using this technology platform.”

Bioasis CEO Deborah Rathjen noted that the neurological complications of LSDs remain largely untreatable when peripheral symptoms of diseases respond to enzyme replacement therapy. 

“Our xB3 BBB drug delivery platform has the potential to significantly advance the treatment of LSDs and the use of enzyme replacement therapy, solving one of the major unmet needs and improving the lives of patients,” Rathjen added.

--UPDATES to ADD stock prices--

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Bioasis Technologies Inc.

Price: 0.28 USD

Market: OTCQB
Market Cap: $17.8 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...



Full interview: Bioasis Technologies new CEO says favorable response from...

Bioasis Technologies Inc (OTCQB:BIOAF) (TSX.V:BTI) CEO Dr. Deborah Rathjen tells Proactive the pre-clinical biopharma group has received positive feedback from the FDA on its pre-investigational new drug (IND) application for its xB3-001 therapy for the treatment of patients with a type of...

on 7/8/19

2 min read